BPC-157 vs Ipamorelin vs Mod GRF 1-29
A three-way comparison to help you find the right peptide for your research goals.
BPC-157
Body Protection Compound-157 is a synthetic peptide derived from a protein found in human gastric juice. It has shown remarkable healing properties in research studies.
Full details →Ipamorelin
Ipamorelin is a selective growth hormone secretagogue that stimulates the release of growth hormone from the pituitary gland without significantly affecting cortisol or prolactin.
Full details →Mod GRF 1-29
Mod GRF 1-29 (Modified GRF 1-29, also called CJC-1295 without DAC or Tetrasubstituted GRF 1-29) is a modified growth hormone-releasing hormone analog with improved stability over natural GHRH.
Full details →Side-by-Side Comparison
| Aspect | BPC-157 | Ipamorelin | Mod GRF 1-29 |
|---|---|---|---|
| Mechanism | BPC-157 works through multiple pathways including upregulation of growth factor expression, nitric oxide system modulation, and promotion of angiogenesis. It enhances tendon-to-bone healing and supports the formation of new blood vessels. | Acts as a ghrelin mimetic, binding to the ghrelin receptor (GHS-R) in the pituitary to stimulate GH release. Highly selective with minimal effect on other hormones. | Binds to GHRH receptors in the pituitary gland to stimulate growth hormone release. Four amino acid substitutions improve resistance to enzymatic degradation while maintaining biological activity. |
| Typical Dosage | Typical research dosages range from 250-500mcg administered 1-2 times daily. Both subcutaneous and oral administration have been studied. | Typical dosing ranges from 200-300mcg administered 2-3 times daily, often combined with CJC-1295. | Typical dosing: 100-300mcg administered 2-3 times daily, usually combined with a GHRP like Ipamorelin for synergistic effects. |
| Administration | Can be administered subcutaneously near the injury site or systemically. Stable in gastric juice, making oral administration viable. | Subcutaneous injection. Best results when administered fasted or before sleep. Often stacked with GHRH peptides. | Subcutaneous injection. Best administered on empty stomach. Short half-life (~30 minutes) necessitates multiple daily doses, unlike DAC version. |
| Side Effects | Generally well-tolerated in research. Some reports of mild nausea or dizziness at higher doses. | Generally well-tolerated. May cause mild headaches, lightheadedness, or increased hunger initially. | Flushing, headache, dizziness, and injection site reactions. Generally well-tolerated. May cause water retention. |
| Best For |
What They Have in Common
BPC-157, Ipamorelin, Mod GRF 1-29 are all commonly used for:
Key Differences
Unique to Ipamorelin:
Unique to Mod GRF 1-29:
Detailed Analysis
Commonalities
Both BPC-157 and Ipamorelin are commonly used for Muscle Growth, Recovery & Healing.
Which Should You Choose?
BPC-157 has stronger evidence for Recovery & Healing. Ipamorelin has stronger evidence for Muscle Growth.
Commonalities
Both BPC-157 and Mod GRF 1-29 are commonly used for Muscle Growth, Recovery & Healing.
Which Should You Choose?
BPC-157 has stronger evidence for Recovery & Healing. Mod GRF 1-29 has stronger evidence for Muscle Growth.
Commonalities
Both Ipamorelin and Mod GRF 1-29 are commonly used for Muscle Growth, Fat Loss, Recovery & Healing, Sleep Quality.
Which Should You Choose?
Ipamorelin has stronger evidence for Fat Loss, Sleep Quality.